End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1 NZD | +1.01% | -1.96% | -32.43% |
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Its low valuation, with P/E ratio at 8.57 and 7.56 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- Sales forecast by analysts have been recently revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.43% | 564M | C | ||
+14.24% | 573B | C+ | ||
+14.86% | 310B | C+ | ||
+14.14% | 254B | C+ | ||
+19.14% | 184B | B- | ||
+24.83% | 172B | B- | ||
+6.62% | 163B | C+ | ||
+8.09% | 150B | B- | ||
-8.45% | 142B | B- | ||
+11.74% | 139B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HGH Stock
- Ratings Heartland Group Holdings Limited